ABBVIE
π«π·France
- Country
- π«π·France
- Ownership
- -
- Established
- 2013-01-01
- Employees
- -
- Market Cap
- $346B
- Website
- http://www.abbvie.com
A Study of Adalimumab After Dose Escalation in Japanese Subjects With Crohn's Disease
- First Posted Date
- 2013-10-09
- Last Posted Date
- 2016-04-12
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 28
- Registration Number
- NCT01958827
Duodopa Home Titration Using Telemedicine: Evaluation of Use of Resources
Completed
- Conditions
- First Posted Date
- 2013-10-08
- Last Posted Date
- 2016-02-23
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 15
- Registration Number
- NCT01956032
Special Investigation in Patients With Ulcerative Colitis
Completed
- Conditions
- First Posted Date
- 2013-09-23
- Last Posted Date
- 2019-05-13
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 1621
- Registration Number
- NCT01947816
A Study of ABT-165 in Subjects With Solid Tumors
Phase 1
Completed
- Conditions
- Interventions
- First Posted Date
- 2013-09-19
- Last Posted Date
- 2023-12-15
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 101
- Registration Number
- NCT01946074
- Locations
- πΊπΈ
HonorHealth Research Institute - Pima /ID# 105677, Scottsdale, Arizona, United States
πΊπΈUniversity of California, Los Angeles /ID# 141389, Los Angeles, California, United States
πΊπΈScottsdale Healthcare /ID# 105678, Scottsdale, Arizona, United States
A Multipart, Open-label Study to Evaluate the Safety and Efficacy of ABT-450/r/ABT-267 With and Without ABT-333 Coadministered With and Without Ribavirin in Adult With Genotype 1 or 4 Hepatitis C Virus (HCV) Infection and Human Immunodeficiency Virus, Type 1 Coinfection
- First Posted Date
- 2013-09-11
- Last Posted Date
- 2021-07-12
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 318
- Registration Number
- NCT01939197
A Phase 3 Study of Fluvoxamine (SME3110) in Pediatric/Adolescent Patients With Obsessive Compulsive Disorder
Phase 3
Completed
- Conditions
- Interventions
- First Posted Date
- 2013-09-02
- Last Posted Date
- 2017-12-04
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 38
- Registration Number
- NCT01933919
A Global Phase 3 Study to Evaluate the Safety and Efficacy of Elagolix in Subjects With Moderate to Severe Endometriosis-Associated Pain
- First Posted Date
- 2013-08-29
- Last Posted Date
- 2018-09-07
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 815
- Registration Number
- NCT01931670
An Open-label, Single Arm, Phase 2 Study to Evaluate ABT-450/r/ABT-267 and ABT-333 With Ribavirin (RBV) in Adults With Genotype 1 HCV Infection Taking Methadone or Buprenorphine
Phase 2
Completed
- Conditions
- Interventions
- First Posted Date
- 2013-07-30
- Last Posted Date
- 2018-05-30
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 38
- Registration Number
- NCT01911845
Safety, Tolerability, and Pharmacokinetics of ABT-354 in Subjects With Mild-to-Moderate Alzheimer's Disease on Stable Doses of Acetylcholinesterase Inhibitors
- First Posted Date
- 2013-07-25
- Last Posted Date
- 2013-12-11
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 20
- Registration Number
- NCT01908010
- Locations
- πΊπΈ
Site Reference ID/Investigator# 106999, Miami, Florida, United States
πΊπΈSite Reference ID/Investigator# 107000, Overland Park, Kansas, United States
πΊπΈSite Reference ID/Investigator# 106998, Orlando, Florida, United States
A Safety and Efficacy Trial of Multiple Dosing Regimens of ABT-719 for the Prevention of Acute Kidney Injury in Subjects Undergoing High Risk Surgery
Phase 2
Terminated
- Conditions
- Interventions
- First Posted Date
- 2013-07-12
- Last Posted Date
- 2014-06-06
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 56
- Registration Number
- NCT01897519
- Locations
- πΊπΈ
Site Reference ID/Investigator# 103356, Boston, Massachusetts, United States
πΊπΈSite Reference ID/Investigator# 102020, Cleveland, Ohio, United States
πΊπΈSite Reference ID/Investigator# 103355, Columbus, Ohio, United States
Β© Copyright 2024. All Rights Reserved by MedPath